New hope for tough myeloma: early trial of BP2202 begins
Disease control
Not yet recruiting
This early-stage trial is testing a new drug called BP2202 in 24 people with multiple myeloma that has come back or no longer responds to standard treatments. The main goal is to see if BP2202 is safe and to find the best dose. Researchers will also watch for any signs that the d…
Phase: PHASE1 • Sponsor: BrightPath Biotherapeutics Co., Ltd. • Aim: Disease control
Last updated Jul 02, 2026 03:00 UTC